497 related articles for article (PubMed ID: 18715665)
41. The transforming growth factor-beta high-producer genotype is associated with response to hepatitis C virus-specific therapy in HIV-positive patients with acute hepatitis C.
Nattermann J; Vogel M; Nischalke HD; Danta M; Ahlenstiel G; Michalk M; Sauerbruch T; Rockstroh JK; Spengler U;
AIDS; 2008 Jul; 22(11):1287-92. PubMed ID: 18580607
[TBL] [Abstract][Full Text] [Related]
42. Hepatitis B therapies and antiviral resistance detection and management.
Holness G; Carriero DC; Dieterich DT
Expert Rev Gastroenterol Hepatol; 2009 Dec; 3(6):693-9. PubMed ID: 19929588
[TBL] [Abstract][Full Text] [Related]
43. [Clinical examinations based on nucleic acids of hepatitis viruses].
Tanaka Y; Mizokami M
Rinsho Byori; 2006 Nov; 54(11):1164-71. PubMed ID: 17240839
[TBL] [Abstract][Full Text] [Related]
44. Customizing the management of chronic hepatitis B virus infection.
Gish RG; Perrillo RP; Jacobson IM
Semin Liver Dis; 2007 Aug; 27 Suppl 1():9-17. PubMed ID: 17701845
[TBL] [Abstract][Full Text] [Related]
45. Influence of hepatitis B virus genotypes on the response to antiviral therapies.
Akuta N; Kumada H
J Antimicrob Chemother; 2005 Feb; 55(2):139-42. PubMed ID: 15618285
[TBL] [Abstract][Full Text] [Related]
46. [Hepatitis C-virus --virus kinetics and resistance mechanisms].
Herrmann E; Sarrazin C
Z Gastroenterol; 2004 May; 42(5):387-96. PubMed ID: 15136939
[TBL] [Abstract][Full Text] [Related]
47. Tailored treatment for hepatitis C.
Berg T
Clin Liver Dis; 2008 Aug; 12(3):507-28, vii-viii. PubMed ID: 18625426
[TBL] [Abstract][Full Text] [Related]
48. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management.
Lok AS; Zoulim F; Locarnini S; Bartholomeusz A; Ghany MG; Pawlotsky JM; Liaw YF; Mizokami M; Kuiken C;
Hepatology; 2007 Jul; 46(1):254-65. PubMed ID: 17596850
[TBL] [Abstract][Full Text] [Related]
49. Viral hepatitis and HIV coinfection.
Sulkowski MS
J Hepatol; 2008 Feb; 48(2):353-67. PubMed ID: 18155314
[TBL] [Abstract][Full Text] [Related]
50. Drug-resistant viral hepatitis.
Wright M; Main J; Thomas HC
J Infect; 2000 Jul; 41(1):1-4. PubMed ID: 10942634
[No Abstract] [Full Text] [Related]
51. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
[TBL] [Abstract][Full Text] [Related]
52. Clinical characteristics and current management of hepatitis B and C in China.
Sun YT; Zhang YX; Tang H; Mao Q; Wang XZ; Zhang LY; Chen H; Zhong YN; Lin SM; Zhang DZ
World J Gastroenterol; 2014 Oct; 20(37):13582-90. PubMed ID: 25309089
[TBL] [Abstract][Full Text] [Related]
53. Identification of hepatitis C virus genotype 6 in Korean patients by analysis of 5' untranslated region using a matrix assisted laser desorption/ionization time of flight-based assay, restriction fragment mass polymorphism.
Oh HB; Kim SO; Cha CH; Hong SP; Folk WR; Kim KM; Suh DJ
J Med Virol; 2008 Oct; 80(10):1712-9. PubMed ID: 18712825
[TBL] [Abstract][Full Text] [Related]
54. Present and future therapy for hepatitis C virus.
Cornberg M; Deterding K; Manns MP
Expert Rev Anti Infect Ther; 2006 Oct; 4(5):781-93. PubMed ID: 17140355
[TBL] [Abstract][Full Text] [Related]
55. Use of virologic assays in the diagnosis and management of hepatitis C virus infection.
Chevaliez S; Pawlotsky JM
Clin Liver Dis; 2005 Aug; 9(3):371-82, v. PubMed ID: 16023971
[TBL] [Abstract][Full Text] [Related]
56. Designing a low-cost drug resistance database for viral hepatitis.
Kuiken C
Antivir Ther; 2010; 15(3 Pt B):517-20. PubMed ID: 20516573
[TBL] [Abstract][Full Text] [Related]
57. Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients.
Yeh ML; Huang CI; Huang CF; Hsieh MH; Liu TW; Lin YH; Liang PC; Hsieh MY; Lin ZY; Chen SC; Huang JF; Kuo PL; Dai CY; Yu ML; Chuang WL
J Infect Dis; 2019 Apr; 219(8):1224-1233. PubMed ID: 30452671
[TBL] [Abstract][Full Text] [Related]
58. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
Nübling CM; Unkelbach U; Chudy M; Seitz R
Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
[TBL] [Abstract][Full Text] [Related]
59. The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.
Meuleman P; Leroux-Roels G
Antiviral Res; 2008 Dec; 80(3):231-8. PubMed ID: 18706933
[TBL] [Abstract][Full Text] [Related]
60. Rethinking therapeutic decisions for hepatitis B infection in Syria: insights into molecular monitoring.
Habbal W; Monem F
J Infect Dev Ctries; 2012 Oct; 6(10):744-7. PubMed ID: 23103897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
